Pharmaceutical Company Invests in Beihui Bio-Peak Pharmaceutical Plate to Expand its Territory
Release time:
2020-07-31
News from this newspaper 2# March 28 , the 10 meeting of the ninth board of directors of the group company deliberated and passed the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing the Chairman". On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation.
Beihui Biology was formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through cooperation with Yale University, we have obtained patent authorization and commercial development license for the new anticancer chemical drug troxacitabine (trokacitabine )(the national clinical approval for the new drug has been obtained in 2016 ), the anti-hepatitis B chemical drug clevudine (Clevudine ).
Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biological Holding Company, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly established by the Chinese government and foreign governments in Guangxi. It covers an area of 214.46 mu and has basically completed the production workshops of percolation, tincture, solid preparation, liquid preparation and other dosage forms, at present, it has entered the GMP certification stage. Guanghui Pharmaceutical has 77 drug approvals mainly for proprietary Chinese medicine preparations. Its main products include Huoxiang Zhengqi Water, Shidishui, Chen Xianglu Bailu Tablets, Compound Pearl Jiedu Oral Liquid, Yigan Mingmu Oral Liquid, etc. Among them, Yigan Mingmu Oral Liquid and Pearl Jiedu Oral Liquid are exclusive products.
According to the cooperation agreement, when the agreed preconditions are met, Jianfeng Pharmaceutical plans to increase the capital of Beihui Biology in four phases. After the agreement comes into effect, it will make the first phase of investment and will contribute ,000 yuan to increase the capital of Beihui Biology in 2,000 shares (accounting for 20% of shares); the second phase contributed ,8600 yuan to increase ,2000 shares of Beihui Biology, and at the same time contributed ,3010 yuan to transfer ,700 shares of Beihui Biology. In the third and fourth phases, the capital increase was ,1400 shares respectively. The capital increase price was determined through negotiation based on the evaluation value of Beihui Biology at that time. If the capital increase and equity transfer are all completed, Peak Pharmaceuticals will hold Beihui Bio 7500 shares (accounting for 50.68% of the equity, the calculation of the equity ratio does not take into account the introduction of other investors). The next few phases of investment will be implemented in stages according to the investment prerequisites agreed in the agreement, the progress of product development, the operation of the target company and other factors.
This cooperation is based on the company's strategic policy of "cooperating and innovating to strengthen the main business, standardizing science and seeking development". It is the specific implementation of expanding and strengthening the pharmaceutical business, which will help to further enhance the new drug research and development capability of Jianfeng Pharmaceutical and further expand the scale of the company's pharmaceutical business. (Zhou Hengbin)
More information
Daye Peak Opens "Standard Year"
After the 2019 overhaul ended in early March, Daye Jianfeng Cement Company immediately launched the "Standard Year" activity to carry out standardized rectification in view of a series of defects and problems in the daily management process. The goal of the "Standard Year" activity is to target specific issues that affect employees' work efficiency and safe and environmentally friendly production. Through the formulation of institutionalized work standards, further standardize employees' various operations, improve operational efficiency, and improve grassroots management execution, so as to achieve The purpose of improving the company's image, reducing costs, improving efficiency, and increasing benefits. In order to ensure the smooth progress of the activities, daye peak has set up a promotion team headed by general manager Zhang fengliang to be responsible for the overall promotion of the "standard year" activities, mainly including revising the activity plan, summarizing the standardized implementation standards of various departments, implementing the plan, supervising the implementation progress, evaluating the implementation effect, collecting suggestions and opinions in the implementation process, etc. Based on the foundation, aiming at the details and solving problems is a major feature of Daye peak's "standard year" activity. For example, the "Flange Sealing Operation Standard", which is currently being tried out, not only puts forward standardization requirements for such a "trivial matter" in equipment management as flange sealing, but also attaches "model" photos to make it clear to mechanics What should be done and what should be done. However, this "small standard" aims at three problems: leakage at the production site, extensive mechanic work and waste of materials. Once it becomes the behavior habit of employees, the hygiene and cost control at the production site are bound to be improved. It is understood that Daye peak "standard year" activities plan to continue for three years to promote, activities
2020
07-30
Shanghai North Carolina Jointly Builds Dongto Pharmaceutical Ecological Circle
News from our newspaper On the afternoon of March 26, the "2019 Dongzhi Pharmaceutical Industry Development Forum" co-sponsored by the Pharmaceutical Finance Circle and Shanghai Beika Pharmaceutical Technology Co., Ltd. was held in Dongzhi County, Anhui Province. More than 40 pharmaceutical industry entrepreneurs gathered together., To provide advice and suggestions for the future development of the pharmaceutical industry in Dongzhi County. At present, the pharmaceutical finance circle is an industry organization with certain influence in the field of biomedicine in China. It brings together high-end pharmaceutical industry elites and biomedical enterprises, and is committed to building a pharmaceutical industry ecosystem. With the concept of "co construction, co creation, win-win and sharing", it solves the common key problems of projects, capital and talents in the development of biomedicine, and forms a new ecology in the field of enterprise services. "2019 Dongzhi Pharmaceutical Industry Development Forum" is an important part of the "Anhui Business Investigation Tour" organized by Shanghai Beika and Pharmaceutical Finance Circle. On the morning of the 26th, the delegation visited New North Card Chemical, Zhongwang Pharmaceutical and other enterprises. Lou Xiaohua, executive deputy general manager of North Carolina Company, introduced the current development status of the company, the complete equipment and facilities and standardized management of the two companies, and the business philosophy of technological innovation as the core and "concentration, conscience, and anti-tumor leader" as its own responsibility. It was unanimously affirmed by the members of the delegation. Before the official start of the forum, Huang Jinlong, deputy general manager of the group company and general manager of Jianfeng Pharmaceutical, delivered a speech on behalf of Jianfeng Group, expressing gratitude to the county party committee and county government for the support of the "Dongzhi Pharmaceutical Development Forum" and to all the entrepreneurs who attended the meeting. Welcome, and give a brief introduction to why Jianfeng Group chose to invest in Dongzhi, and invite all colleagues to join in the development of Dongzhi medicine. In academic exchanges,
2020
07-31
Daye Peak Opens "Standard Year"
After the 2019 overhaul ended in early March, Daye Jianfeng Cement Company immediately launched the "Standard Year" activity to carry out standardized rectification in view of a series of defects and problems in the daily management process. The goal of the "Standard Year" activity is to target specific issues that affect employees' work efficiency and safe and environmentally friendly production. Through the formulation of institutionalized work standards, further standardize employees' various operations, improve operational efficiency, and improve grassroots management execution, so as to achieve The purpose of improving the company's image, reducing costs, improving efficiency, and increasing benefits. In order to ensure the smooth progress of the activities, daye peak has set up a promotion team headed by general manager Zhang fengliang to be responsible for the overall promotion of the "standard year" activities, mainly including revising the activity plan, summarizing the standardized implementation standards of various departments, implementing the plan, supervising the implementation progress, evaluating the implementation effect, collecting suggestions and opinions in the implementation process, etc. Based on the foundation, aiming at the details and solving problems is a major feature of Daye peak's "standard year" activity. For example, the "Flange Sealing Operation Standard", which is currently being tried out, not only puts forward standardization requirements for such a "trivial matter" in equipment management as flange sealing, but also attaches "model" photos to make it clear to mechanics What should be done and what should be done. However, this "small standard" aims at three problems: leakage at the production site, extensive mechanic work and waste of materials. Once it becomes the behavior habit of employees, the hygiene and cost control at the production site are bound to be improved. It is understood that Daye peak "standard year" activities plan to continue for three years to promote, activities
2020
07-31
Guizhou Huangping Cement Project Started
The expansion of the peak cement industry has taken substantial steps. A few days ago, the opening ceremony of the peak Guizhou Huangping cement project was held in Gulong Town, Huangping County. Huangping County is located in the southeast of Guizhou Province and the northwest of Qiandongnan Miao and Dong Autonomous Prefecture. It is rich in barite, limestone, gypsum, bauxite, mercury and other mineral resources. At the end of 2018, the board of directors of the group company passed the proposal to acquire all the shares of Guizhou Mingchuan company. After the acquisition is completed, Mingchuan Company will become a wholly-owned subsidiary of Jianfeng and will continue to invest about 0.65 billion yuan to build a new dry cement production line with a daily output of 4500 tons of cement clinker in an off-site technological transformation project (with waste heat power generation). On February 28, 2019, the Company and the former shareholders of Mingchuan completed the relevant asset transfer, equity transfer and industrial and commercial change registration procedures. Before the Spring Festival, the preparatory team with Hu Hongwei as the team leader and Lu Hongzheng as the deputy team leader has been stationed at the project site to carry out a series of preparatory work. The Huangping cement project is an important measure to strengthen the development of the company's main business according to the company's strategic policy of "strengthening the main business through cooperation and innovation, standardizing science and seeking development. The construction of the project will strictly follow the requirements of new industrialization, adopt advanced new dry-process rotary kiln production technology and industrial waste slag comprehensive utilization technology, which will not only bring economic and social benefits to the local area, but also further expand the scale of peak cement business. Become a new profit growth point of the company. Yu Jianhong, general manager of the group company, Huang Jinlong, deputy general manager, Zhu Jianwei, secretary of the board of directors, personnel of the preparation team of Huangping cement project, relevant leaders of Huangping County and Gulong Town, and person in charge of the project construction unit participated in the construction.
2020
07-31
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-31
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-30